Business
-
GlaxoSmithKline has exercised an option for an exclusive license to develop inhaled therapies using Liquidia Techonologies’ PRINT particle engineering technology, Liquidia said. The option was included in a collaboration deal the two companies signed in… Read more . . .
-
Teva Pharmaceutical has acquired privately held Gecko Health Innovations and its CareTRx asthma and COPD management system. CareTRx works with a monitoring device called GeckoCap that attaches to an MDI plus a mobile phone app.… Read more . . .
-
Inhaled drug developer Alexza Pharmaceuticals has hired a financial advisor “to assist in exploring strategic options to enhance stockholder value,” the company said. Options being explored include selling corporate assets, a strategic business combination, or… Read more . . .
-
Natesto intranasal testosterone developer Trimel Pharmaceuticals Corporation has announced that it has a new name: Acerus Pharmaceuticals Corporation. Acerus President and CEO Tom Rossi commented, “We are very excited to officially launch our new corporate… Read more . . .
-
Invion Limited, which is developing several inhaled drugs, has announced a private placement in which it is issuing 71.5 million ordinary shares at $0.014 per share to “a US institutional investor” for a total of… Read more . . .
-
Aegis Therapeutics has announced that it received its first Russian patent (No. 2554814), titled, “Compositions for drug administration.” The patent covers formulations of triptans for the treatment of migraine that use Aegis’ Intravail transmucosal absorption… Read more . . .
-
Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT), which recently received orphan drug status in Europe for its inhaled nitric oxide for the treatment of cystic fibrosis, has filed with the US Securities and Exchange Commission… Read more . . .
-
Skyepharma has reported that in-market sales of the flutiform fluticasone/formoterol MDI for the first 6 months of 2015 have totaled €65.1 million, up from €28.4 million in the first half of 2014, and the directors… Read more . . .
-
Raptor Pharmaceutical Co. plans to launch Quinsair inhaled levofloxacin inhalation solution in Europe and Canada by mid-2016, the company said after announcing that it has agreed to pay Tripex Pharmaceuticals $68.4 million upfront and up… Read more . . .
-
MannKind Corporation has announced the appointment of former Mylan CMO Raymond Urbanski as its Chief Medical Officer. Urbanski has also held positions at Metabolix, Pfizer, and Suntory, with experience in drug development for oncology, rheumatology,… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK

